FDA Approves Zetonna

FRIDAY, January 20, 2012 - The U.S. Food and Drug Administration today approved Zetonna (ciclesonide) nasal aerosol to treat the symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

FDA Approves Subsys

The US Food and Drug Administration has approved Subsys (fentanyl) sublingual spray. Subsys is a sublingually-administered formulation of fentanyl which provides relief to patients who experience episodes of breakthrough cancer pain. Breakthrough cancer pain is characterized by sudden, often unpredictable, episodes of intense pain which can peak in severity at three to five minutes despite background pain medication. Subsys is approved in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

FDA Approves Anturol

The U.S. Food and Drug Administration (FDA) has approved Anturol (oxybutynin) topical gel 3% for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

What do you kow about :Guillain–Barré syndrome

Sometimes called Landry's paralysis, is an acute polyneuropathy, a disorder affecting the peripheral nervous system. Ascending paralysis, weakness beginning in the feet and hands and migrating towards the trunk, is the most typical symptom, and some subtypes cause change in sensation or pain as well as dysfunction of the autonomic nervous system.

WHAT DO YOU KNOW ABOUT: OVARIAN HYPERSTIMULATION SYNDROME

Introduction

Ovarian hyperstimulation syndrome (OHSS) occurs in the luteal phase of the cycle after multifollicular stimulation and hCG administration.  It is characterised by multiple corpus luteum cysts and transudation of plasma from blood across serosa, particularly the peritoneum.  OHSS most frequently occurs following ovulation induction therapy and superovulation for assisted conception treatments, but occasionally in naturally occurring multiple pregnancy, hydatidiform mole and choriocarcinoma.  It is the commonest serious side effect of ovarian stimulation using gonadotrophins but is very uncommon with clomiphene.

Vasopressors used in shock

A vasopressor causes vasoconstriction and an inotrope increases the force of cardiac contraction.

The role of inotropes and vasopressors is very important in the resuscitation of a patient, prescribing these can best be done by an experienced physician. Every doctor has his or own method of starting the patient on these drugs. Most of the hospitals have there own protocol.

In this article we will discuss the role of the three most commonly given inotropes and vasopressors.

Canadian BOARD Schedule of Fees - Pharmacists 2012

Fees must be paid in Canadian funds by certified cheque, money order or bank draft. Visa and MasterCard are accepted for document evaluation & examination fees if you apply using PEBC's online application.

Pharmacist Document Evaluation  $530

The Pharmacist Evaluating Examination  $515
Additional fee to write in London, UK  $365
Site Change, Evaluating Examination:  $50
The Pharmacist Evaluating Examination Re-scoring  $75

The Pharmacist Qualifying Examination - Part I MCQ:  $400 
The Pharmacist Qualifying Examination - Part II OSCE:  $1520
Site Change, The Pharmacist Qualifying Examination Part I (MCQ):  $50
Site Change, The Pharmacist Qualifying Examination Part II (OSCE):  $100
The Pharmacist Qualifying Examination - Part I MCQ Re-scoring  $75
The Pharmacist Qualifying Examination - Part II OSCE Re-scoring  $150

NSF Cheque fee  $50

Certificate Replacement  $100

Sending Licensing Statement/Good Standing Certificate to Provincial Licensing Authority  $50
 

FDA Approves Intermezzo

The U.S. Food and Drug Administration has approved Intermezzo (zolpidem tartrate sublingual tablets) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep.

FDA Approves Eylea

The U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

FDA Approvals: Tadalafil for Benign Prostatic Hyperplasia

Clinical Context

Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2003 to treat erectile dysfunction (ED). The FDA has now expanded the approved indications to include benign prostatic hyperplasia (BPH), either alone or in combination with ED.